Edward L Barnes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2344207/publications.pdf

Version: 2024-02-01

85 papers

3,071 citations

304743

22

h-index

52 g-index

87 all docs

87 docs citations

87 times ranked

3755 citing authors

#	Article	IF	Citations
1	Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. Gastroenterology, 2019, 156, 254-272.e11.	1.3	1,040
2	Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021. Gastroenterology, 2022, 162, 621-644.	1.3	254
3	Depression Is Associated With More Aggressive Inflammatory Bowel Disease. American Journal of Gastroenterology, 2018, 113, 80-85.	0.4	121
4	Are Patients with Inflammatory Bowel Disease on Chronic Immunosuppressive Therapy at Increased Risk of Cervical High-grade Dysplasia/Cancer? A Meta-analysis. Inflammatory Bowel Diseases, 2015, 21, 1089-1097.	1.9	112
5	The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis. Gut Microbes, 2017, 8, 574-588.	9.8	102
6	Narcotic use for inflammatory bowel disease and risk factors during hospitalization. Inflammatory Bowel Diseases, 2012, 18, 869-876.	1.9	86
7	Impact of capsule endoscopy on management of inflammatory bowel disease: A single tertiary care center experience. Inflammatory Bowel Diseases, 2011, 17, 1855-1862.	1.9	73
8	The Incidence and Definition of Crohn's Disease of the Pouch: A Systematic Review and Meta-analysis. Inflammatory Bowel Diseases, 2019, 25, 1474-1480.	1.9	68
9	Modifiable Risk Factors for Hospital Readmission Among Patients with Inflammatory Bowel Disease in a Nationwide Database. Inflammatory Bowel Diseases, 2017, 23, 875-881.	1.9	67
10	Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. Gastroenterology, 2018, 155, 1098-1108.e9.	1.3	67
11	Perioperative and Postoperative Management of Patients With Crohn's Disease and Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1356-1366.	4.4	65
12	High Dietary Intake of Specific Fatty Acids Increases Risk of Flares in Patients With Ulcerative Colitis in Remission During Treatment With Aminosalicylates. Clinical Gastroenterology and Hepatology, 2017, 15, 1390-1396.e1.	4.4	64
13	Effects of Race and Ethnicity on Diagnosis and Management of Inflammatory Bowel Diseases. Gastroenterology, 2021, 160, 677-689.	1.3	64
14	Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort. Inflammatory Bowel Diseases, 2019, 25, 767-774.	1.9	60
15	Predictors of Clinical Response and Remission at $1 \hat{A} Y = 1 $	2.3	56
16	Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort. Inflammatory Bowel Diseases, 2019, 25, 1569-1576.	1.9	50
17	Incidence, Risk Factors, and Outcomes of Pouchitis and Pouch-Related Complications in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1583-1591.e4.	4.4	46
18	Pouch-Related Symptoms and Quality of Life in Patients with Ileal Pouch–Anal Anastomosis. Inflammatory Bowel Diseases, 2017, 23, 1218-1224.	1.9	42

#	Article	IF	Citations
19	Hospitalizations for Acute Myocardial Infarction Are Decreased Among Patients with Inflammatory Bowel Disease Using a Nationwide Inpatient Database. Inflammatory Bowel Diseases, 2016, 22, 2229-2237.	1.9	40
20	Scope of Burnout Among Young Gastroenterologists and Practical Solutions from Gastroenterology and Other Disciplines. Digestive Diseases and Sciences, 2019, 64, 302-306.	2.3	34
21	Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis. Inflammatory Bowel Diseases, 2020, 26, 1225-1231.	1.9	30
22	New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes. Inflammatory Bowel Diseases, 2016, 22, 2956-2965.	1.9	27
23	Are Anti-Tumor Necrosis Factor Trough Levels Predictive of Mucosal Healing in Patients With Inflammatory Bowel Disease?. Journal of Clinical Gastroenterology, 2016, 50, 733-741.	2.2	23
24	Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study. Clinical Gastroenterology and Hepatology, 2022, 20, 2399-2401.e4.	4.4	23
25	The Burden of Hospital Readmissions among Pediatric Patients with Inflammatory Bowel Disease. Journal of Pediatrics, 2017, 191, 184-189.e1.	1.8	22
26	High Patient Activation Is Associated With Remission in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1248-1254.	1.9	22
27	Asians Have More Perianal Crohn Disease and Ocular Manifestations Compared with White Americans. Inflammatory Intestinal Diseases, 2017, 2, 147-153.	1.9	21
28	Lack of Difference in Treatment Patterns and Clinical Outcomes Between Black and White Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2634-2640.	1.9	20
29	Systematic Review and Meta-analysis of Outcomes After Ileal Pouch-anal Anastomosis in Primary Sclerosing Cholangitis and Ulcerative Colitis. Journal of Crohn's and Colitis, 2021, 15, 1272-1278.	1.3	20
30	Urgency and Its Association With Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis. American Journal of Gastroenterology, 2022, 117, 769-776.	0.4	20
31	Minority Pediatric Patients with Inflammatory Bowel Disease Demonstrate an Increased Length of Stay. Inflammatory Bowel Diseases, 2017, 23, 2189-2196.	1.9	18
32	An active learning curriculum improves fellows' knowledge and faculty teaching skills. Advances in Medical Education and Practice, 2017, Volume 8, 359-364.	1.5	18
33	Delayed Ileal Pouch Anal Anastomosis Has a Lower 30-Day Adverse Event Rate: Analysis From the National Surgical Quality Improvement Program. Inflammatory Bowel Diseases, 2018, 24, 1833-1839.	1.9	16
34	Trends and Characteristics of Clinical Trials Participation for Inflammatory Bowel Disease in the United States: A Report From IBD Partners. Crohn's & Colitis 360, 2020, 2, otaa023.	1.1	15
35	Increased colonic expression of ACE2 associates with poor prognosis in Crohn's disease. Scientific Reports, 2021, 11, 13533.	3.3	14
36	Tofacitinib in the Treatment of Crohn's-Like Disease of the Pouch. American Journal of Gastroenterology, 2020, 115, 2116-2117.	0.4	14

#	Article	IF	Citations
37	Test Characteristics of Cross-sectional Imaging and Concordance With Endoscopy in Postoperative Crohn's Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 2327-2336.e4.	4.4	13
38	Increasing Incidence of Pouchitis Between 1996 and 2018: A Population-Based Danish Cohort Study. Clinical Gastroenterology and Hepatology, 2023, 21, 192-199.e7.	4.4	13
39	Decreased Colonic Activin Receptor-Like Kinase 1 Disrupts Epithelial Barrier Integrity in Patients With Crohn's Disease. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 779-796.	4.5	12
40	Mild neoterminal ileal postâ€operative recurrence of Crohn's disease conveys higher risk for severe endoscopic disease progression than isolated anastomotic lesions. Alimentary Pharmacology and Therapeutics, 2022, 55, 1139-1150.	3.7	12
41	Increasing Incidence of Pediatric Inflammatory Bowel Disease in France: Implications for Etiology, Diagnosis, Prognosis, and Treatment. American Journal of Gastroenterology, 2018, 113, 273-275.	0.4	11
42	Suicidal Behavior Among Hospitalized Adults With Inflammatory Bowel Disease: A United States Nationwide Analysis. Inflammatory Bowel Diseases, 2018, 24, 25-34.	1.9	11
43	A Novel Patient-Reported Outcome-Based Evaluation (PROBE) of Quality of Life in Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2019, 114, 640-647.	0.4	11
44	Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data. International Journal of Clinical Pharmacy, 2021, 43, 1116-1122.	2.1	10
45	Creation of a Case-Finding Definition for Identifying Patients With Acute Pouchitis in Administrative Claims Data. Clinical Gastroenterology and Hepatology, 2021, 19, 842-844.e1.	4.4	9
46	Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults. Diabetes Care, 2019, 42, 2065-2074.	8.6	8
47	Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States. Crohn's & Colitis 360, 2020, 2, otaa039.	1.1	8
48	Intra-abdominal septic complications after ileocolic resection increases risk for endoscopic and surgical postoperative Crohn's disease recurrence. Journal of Crohn's and Colitis, 2022, 16, 1696-1705.	1.3	8
49	Black and White Patients With Inflammatory Bowel Disease Show Similar Biologic Use Patterns With Medicaid Insurance. Inflammatory Bowel Diseases, 2021, 27, 364-370.	1.9	7
50	Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States. Inflammatory Bowel Diseases, 2022, 28, 983-987.	1.9	7
51	Use of blood based biomarkers in the evaluation of Crohn's disease and ulcerative colitis. World Journal of Gastrointestinal Endoscopy, 2015, 7, 1233.	1.2	7
52	A United States expert consensus to standardise definitions, followâ€up, and treatment targets for extraâ€intestinal manifestations in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 1179-1191.	3.7	7
53	Associations of Inflammatory Bowel Disease and Subsequent Cancers in a Population-Based Study of Older Adults in the United States. JNCI Cancer Spectrum, 2022, 6, pkab096.	2.9	7
54	Got Milk? An Unusual Cause of Abdominal Pain. Gastroenterology, 2015, 148, e1-e2.	1.3	6

#	Article	IF	CITATIONS
55	The Usefulness of Serologic Testing for Epstein–Barr Virus Before Initiation of Therapy for Inflammatory Bowel Disease. Gastroenterology, 2017, 153, 1167.	1.3	6
56	The Current State of Care for Black and Hispanic Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases, 2023, 29, 297-307.	1.9	6
57	Sequential Combination Therapy Versus Monotherapy: A Lack of Benefit in Time to Inflammatory Bowel Disease-Related Surgery. Digestive Diseases and Sciences, 2016, 61, 3261-3269.	2.3	4
58	Chronic Antibiotic Dependent Pouchitis Is Associated With Older Age at the Time of Ileal Pouch Anal Anastomosis (J-pouch) Surgery. Crohn's & Colitis 360, 2019, 1, otz029.	1.1	4
59	The Early Experience With Vedolizumab in the United States. Crohn's & Colitis 360, 2019, 1, otz027.	1.1	4
60	Letter: optimising response to ustekinumab therapy for patients with Crohn's disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 906-906.	3.7	4
61	Patients With Pouchitis Demonstrate a Significant Cost Burden in the First Two Years After Ileal Pouch-Anal Anastomosis. Clinical Gastroenterology and Hepatology, 2022, 20, 2908-2910.e2.	4.4	4
62	Relationship Between Stages of Ileal Pouch-Anal Anastomosis, Timing of Restoration of Fecal Continuity, and Pouchitis. Digestive Diseases and Sciences, 2022, 67, 5220-5226.	2.3	4
63	Do Shared Exposures Link the Lungs and Gut? Association Between Asthma and InflammatoryÂBowel Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 1353-1354.	4.4	3
64	Impact of Virtual Interviews on Gastroenterology and Hepatology Fellowship Recruitment. Digestive Diseases and Sciences, 2022, 67, 3464-3465.	2.3	3
65	Antibiotic Use Patterns in the Management of Chronic Pouchitis. Inflammatory Bowel Diseases, 2022, , .	1.9	3
66	Vancomycin Is Effective in the Treatment of Chronic Inflammatory Conditions of the Pouch. Inflammatory Bowel Diseases, 2022, 28, 1610-1613.	1.9	3
67	Development of the Endoscopic Pouch Score for Assessment of Inflammatory Conditions of the Pouch. Clinical Gastroenterology and Hepatology, 2023, 21, 1663-1666.e3.	4.4	3
68	Development of an Inflammatory Bowel Disease-Specific Medication Adherence Instrument and Reasons for Non-adherence. Digestive Diseases and Sciences, 2023, 68, 58-64.	2.3	3
69	How to Create an Unfunded Teaching Fellowship During the Gastroenterology Fellowship That Positively Impacts Subsequent Teaching Activities and Career Path. Gastroenterology, 2017, 152, 689-692.	1.3	2
70	Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2021, Publish Ahead of Print, .	2.2	2
71	Home Infusions for Inflammatory Bowel Disease Are Safe: US Experience and Patient Perspectives. Crohn's & Colitis 360, 2021, 3, otab063.	1.1	2
72	The Cumulative Incidence of Pouchitis in Pediatric Patients With Ulcerative Colitis. Inflammatory Bowel Diseases, 2022, 28, 1332-1337.	1.9	2

#	Article	lF	CITATIONS
73	A Self-management SMS Text Messaging Intervention for People With Inflammatory Bowel Disease: Feasibility and Acceptability Study. JMIR Formative Research, 2022, 6, e34960.	1.4	2
74	Response to Infliximab After Loss of Response to Adalimumab in Crohn's Disease. Inflammatory Bowel Diseases, 2019, 26, e5.	1.9	1
75	Personalized Best: Toward Improving Care in Ulcerative Colitis. Digestive Diseases and Sciences, 2021, 66, 3736-3739.	2.3	1
76	Adjunctive Pharmacotherapy Use in Patients With Ileal Pouch-Anal Anastomosis (IPAA). Crohn's & Colitis 360, 2020, 2, .	1.1	1
77	Treating IBD? Don't Forget that Mental Health Matters. Digestive Diseases and Sciences, 2022, 67, 4321-4323.	2.3	1
78	Response to Levenstein and Prantera. American Journal of Gastroenterology, 2018, 113, 1559.	0.4	0
79	Response to Dai et al. and Gracie et al American Journal of Gastroenterology, 2018, 113, 774-775.	0.4	0
80	Opportunistic Infections and Opportunities for Action. Inflammatory Bowel Diseases, 2020, 26, 301-303.	1.9	0
81	Medical Management of Aggressive Inflammatory Bowel Disease: When Is the Time to Cut Your (and the) Tj ETC 905-910.	91 1 0.78 1.0	4314 rgBT /O O
82	Standardized Approaches to Outcomes after Ileal Pouch-Anal Anastomosis. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	0
83	Transmural Inflammation, Ileitis, and Granulomas at the Time of Proctocolectomy in Patients with Ulcerative Colitis Do Not Predict Future Development of Pouchitis. Inflammatory Intestinal Diseases, 2021, 6, 1-8.	1.9	0
84	Standardizing Healthcare Delivery to Reduce Utilization, the Potential of Evidence-Based Care Pathways. Crohn's & Colitis 360, 2020, 2, .	1.1	0
85	Quality of Care in the Management of Hospitalized Patients with Inflammatory Bowel Disease. , 2022, , 211-223.		O